Mikael Eriksson

Research interests

Publications

• Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes

  JAMA Oncology · 2022 · https://doi.org/10.1001/jamaoncol.2021.6744

• Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities

  Cancer · 2021 · 10.1002/cncr.33618

• Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.07.006

• Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.09.005

• Genetic insights into biological mechanisms governing human ovarian ageing

  Nature · 2021 · https://doi.org/10.1038/s41586-021-03779-7

• Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.08.1995

• Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

  Nature Genetics · 2020 · https://doi.org/10.1038/s41588-019-0537-1

• Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

  European Journal of Cancer · 2019 · 10.1016/j.ejca.2018.11.027

• Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy096

• A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer

  Nature Genetics · 2018 · https://doi.org/10.1038/s41588-018-0132-x

• Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy310

• Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

  The American Journal of Human Genetics · 2018 · https://doi.org/10.1016/j.ajhg.2018.11.002

• Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy095

• Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(16)30214-5

• 15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial ( MCL 2): prolonged remissions without survival plateau

  British Journal of Haematology · 2016 · https://doi.org/10.1111/bjh.14241

• Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer

  Nature Genetics · 2015 · https://doi.org/10.1038/ng.3242

• Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2015.62.9170

• Identification of Novel Genetic Markers of Breast Cancer Survival

  JNCI Journal of the National Cancer Institute · 2015 · https://doi.org/10.1093/jnci/djv081

• Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.60.0734

• Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants

  JNCI Journal of the National Cancer Institute · 2015 · https://doi.org/10.1093/jnci/djv036

• Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation

  Nature Communications · 2014 · https://doi.org/10.1038/ncomms5999

• EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment

  Annals of Oncology · 2014 · 10.1093/annonc/mdu526

• Nordic MCL 2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem‐cell support: still very long survival but late relapses do occur

  British Journal of Haematology · 2012 · https://doi.org/10.1111/j.1365-2141.2012.09174.x

• One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

  JAMA · 2012 · https://doi.org/10.1001/jama.2012.347

• The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

  Blood · 2009 · https://doi.org/10.1182/blood-2009-08-236570

• Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

  Blood · 2008 · https://doi.org/10.1182/blood-2008-03-147025

• Increased concentrations of polychlorinated biphenyls, hexachlorobenzene, and chlordanes in mothers of men with testicular cancer.

  Environmental Health Perspectives · 2002 · 10.1289/ehp.5816

• Soft-tissue sarcomas and exposure to chemical substances: a case-referent study.

  Occupational and Environmental Medicine · 1981 · 10.1136/oem.38.1.27

• Malignant lymphoma and exposure to chemicals, especially organic solvents, chlorophenols and phenoxy acids: a case-control study

  British Journal of Cancer · 1981 · 10.1038/bjc.1981.25

Current projects

No projects listed.